MetaCure

MetaCure is discontinuing customer support of the DIAMOND I (also known as the TANTALUS II) implantable gastric stimulation device. Many of the components used in the device are no longer available, and it is difficult for our company to redesign the device and meet current regulatory requirements. With your help, MetaCure has been able to conduct many years of clinical research using the DIAMOND I device to develop an interventional solution for patients suffering from type 2 diabetes and obesity. We are sincerely grateful for your support and contributions, and intend to use our research and experience to continue searching for an improved solution for these patients.

Customer support for the DIAMOND I will cease June 30, 2018. We recommend that patients implanted with the DIAMOND I speak with their physician to consider removal of the device. Any questions should be directed to Metacure at diamondsupport@metacure.com.

With over ten years of clinical research, MetaCure is one of the first companies to develop and test an active implantable device for patients suffering from type 2 diabetes and obesity. Offering novel solutions to this patient group remains MetaCure’s chief mission. If you are interested in learning more about MetaCure and its activities in the diabetes treatment space, please contact us at contact@metacure.com.